Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tandem bispecific IL-7 receptor agonist antibody

ABSTRACT: Interleukin-7 (IL-7) is essential for T cell immunity, but the therapeutic application of existing IL-7 therapies is limited by narrow therapeutic window and suboptimal pharmacokinetics. To address this, we engineered a fully human tandem bispecific antibody, TB4, that functions as a potent IL-7 receptor (IL-7R) agonist by cross-linking the IL-7Rα and γc subunits. In primary human T cells, TB4 exhibited potent bispecific binding and induced sustained STAT5 signaling, a feature potentially associated with its slow antibody internalization rate. TB4 promoted T cell survival and the preferential expansion of CD4⁺ memory T cells. Notably, transcriptomic analysis revealed that TB4 induces a unique transcriptional signature enriched in genes associated with antiviral and innate immune responses, distinguishing it from native IL-7. These findings highlight TB4 as a promising IL-7R agonist with the potential to act as a subset-specific T cell immunomodulator, shaping both the expansion and functional profile of T cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE307905 | GEO | 2026/06/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Function-Driven Design of a Surrogate Interleukin-2 Receptor Ligand

Project description:We developed an artificial signaling system to enable the assembly of cytokine receptor surrogate ligands. A JAK-STAT5 signaling module—comprising the JAK3-specific γc receptor and a functional IL-2Rβ receptor—was stably expressed in a STAT-deficient cell line. Using a combinatorial antibody library, we screened for receptor binders with selective emphasis on IL-2Rβ affinity. Among various bispecific scaffolds, the single-chain diabody (scDb) format demonstrated superior potency and efficacy, effectively recapitulating native IL-2 ligand activity by inducing functional dimerization of IL-2Rβ and γc receptors. The lead scDb-2d (also termed J9H4) agonist antibody functioned as a surrogate IL-2 receptor ligand, selectively driving Teff and NK cell proliferation and activation.

2025-12-31 | GSE305574 | GEO

Tandem bispecific IL-7 receptor agonist antibody

Project description:Tandem bispecific IL-7 receptor agonist antibody

| PRJNA1327777 | ENA

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists

Project description:The ability to leverage antibodies to agonize disease relevant biological pathways has the potential to unlock new drug targets for clinical investigation. While antibodies have been successful as antagonists, immune mediators, and targeting agents, they are not readily effective at recapitulating the biological activity of natural ligands. Among the important determinants of antibody agonist activity is the geometry of target receptor engagement. Herein, we describe a novel engineering approach inspired by a naturally occurring Fab-Fab homotypic interaction that constrains IgG in a unique i-shaped conformation. i-shaped antibody (iAb) engineering enables potent intrinsic agonism of five tumor necrosis factor receptor superfamily (TNFRSF) targets. When applied to bispecific antibodies against the heterodimeric IL-2 receptor pair, constrained bispecific IgG formats recapitulate IL-2 agonist activity. Thus, iAb engineering represents a new tool to tune agonist antibody function and this work provides a framework for the development of intrinsic antibody agonists with the potential for generalization across broad receptor classes.

2023-12-18 | GSE246602 | GEO

Facile Diversification of Interleukin-2 Pharmacology with Surrogate Agonists

Project description:Cytokines, such as interleukin-2, initiate signaling by dimerizing their receptors into orientations and proximities that induce intracellular signaling. We wished to explore a new pharmacological strategy for cytokine discovery based on variation of receptor dimer geometries using surrogate ligands, since natural cytokines are structurally limited as engineering scaffolds. Here, we report a structurally agonistic approach based on a modular, ‘plug and play’ class of ligands, that is amenable to high-throughout screening. We isolated nanobodies (Nb) and scFvs against human IL-2Rβ and γc, and generated a 40-member combinatorial matrix of tandem single-chain bispecific (IL-2Rβ:γc) molecules. We identified 28 surrogate IL-2 ligands exhibiting a wide range of agonist strengths and biased signaling properties, including cell-type bias for NK expansion and cytotoxity relative to T cells. Crystal structures of select Nb:receptor complexes validated that alternative receptor dimer geometries underly the functional diversification. This “cytokine med-chem” approach is generalizable to many dimeric cell surface receptor systems.

2022-04-27 | GSE183436 | GEO

Translation factor eIF4G2 directs CD8⁺ T cell lineage commitment by selectively enabling the IL-7 receptor response

Project description:Faithful CD8+ T cell lineage commitment depends on sustained IL-7 receptor (IL-7R) signaling. Here, we identify the translation initiation factor eIF4G2 as a specific and essential regulator of this process. Conditional deletion of Eif4g2 in CD4-expressing thymocytes specifically abrogated the expression of the shared IL-7R γ chain (γc) in a 5'/3'-UTR-dependent manner. This was accompanied by reduced expression of IL-7R α chain. The resultant collapse of the IL-7R complex ablated IL-7 signaling, thereby blocking CD8+ lineage commitment. This defect was selective, with TCR signaling and other cytokine receptors remaining intact. Our work establishes that eIF4G2 governs the thymic IL-7R axis and reveals a paradigm whereby a translational factor specifically tunes a key cytokine niche to direct T cell fate.

2026-02-27 | GSE317990 | GEO

IL-7R signalling activates widespread VH and DH gene usage to drive antibody diversity in bone marrow B cells

Project description:Generation of the primary antibody repertoire requires V(D)J recombination of hundreds of gene segments in the immunoglobulin heavy chain (Igh) locus. It has been proposed that interleukin-7 receptor (IL-7R) signalling is necessary for Igh recombination, but this has been challenging to partition from the receptor’s role in B cell survival and proliferation. By generating the first detailed description of the Igh repertoire of murine IL-7Ra-/- bone marrow B cells, we demonstrate that IL-7R signalling profoundly influences VH gene selection during VH-to-DJH recombination. We find skewing towards usage of 3’ VH genes during de novo VH-to-DJH recombination that is more severe than the fetal liver (FL) B cell repertoire, and we now show a role for IL-7R signalling in DH-to-JH recombination. Transcriptome and accessibility analyses suggests reduced expression of B lineage-specific transcription factors (TFs) and their targets, and loss of DH and VH antisense transcription in IL-7Rα-/- B cells. These results refute models suggesting that IL-7R signalling is only required for survival and proliferation, and demonstrate a pivotal role in shaping the Igh repertoire by activating underpinning epigenetic mechanisms.

2021-02-20 | GSE157603 | GEO

IL-7 receptor blockade in human PBMC

Project description:Targeting the expansion and survival of pathogenic memory immune cells is a promising therapy to prevent chronic autoimmune attacks. Interleukin-7 receptor α chain (IL-7Rα) genetic variation were repeatedly associated with susceptibility of several chronic autoimmune and inflammatory diseases. Interleukin-7 (IL-7) is as a critical survival factor for the maintenance of mature T lymphocytes and numerous studies in rodent suggest targeting the IL-7/IL-7Rα pathway holds promise for the treatment of autoimmune diseases or transplant rejection. In this study, we evaluated agonist and antagonist properties of different anti-IL7Rα mAbs recognizing different type of epitope. To determine if agonist/antagonist anti-IL7Rα mAbs could deliver effective agonist signals capable of modifying human T cells, we analyzed by RNA-based-next-generation sequencing (RNA-SEQ) the transcriptome of human PBMC incubated during 3,5 hours with a site-1 (IgG4 #1 or IgG1 #2) or site-1/2b (IgG4) mAbs in the presence or not of exogenous human IL-7 (5 ng/ml). Altogether, transcriptional analysis confirmed that, while site-1 and site-1/2b anti-human IL-7Rα mAbs shared similar antagonist properties, the two site-1 mAbs induced significant human PBMC transcriptional modification compatible with T-cell activation and inflammatory responses associated by the MAPK/ERK pathway.

2018-09-17 | GSE103643 | GEO

Intratumoral delivery of EpCAM-CD3-Fc bispecific antibody with IL-12 and GM-CSF mRNA-lipid nanoparticles (LNPs) blocks both local and distal tumor growth

Project description:Intratumoral delivery of mRNA–lipid nanoparticles (LNPs)–encoded bispecific antibodies and immunomodulatory proteins is a promising strategy for tumor eradication, offering potent local activity with limited toxicity and minimal systemic exposure. In this study, we evaluated two combinations of four immunostimulatory mRNAs and found that intratumoral administration of IL-2 and GM-CSF mRNA–LNPs together with EpCAM-CD3 mRNA–LNPs in OVCAR-5 and PC3 xenograft models significantly reduced not only treated tumors but also distant, untreated lesions. In PC3 tumors, enhanced local and systemic antitumor activity of the three-mRNA–LNP combination was associated with activation of T-cell–related pathways, as revealed by RNA-seq analysis. Key effector genes—including perforin (PRF1), granzyme H (GZMH), CD3E, CD3D, HLA-DPA1, among others—were upregulated following treatment with the bispecific antibody plus immunomodulator mRNA–LNPs, providing mechanistic support for the observed efficacy in both local and distant tumors. Collectively, these data demonstrate that intratumoral delivery of EpCAM-CD3 together with IL-2 and GM-CSF mRNA–LNPs represents a promising approach for future clinical investigation.

2026-09-04 | GSE312815 | GEO

Intratumoral delivery of EpCAM-CD3-Fc bispecific antibody with IL-12 and GM-CSF mRNA-lipid nanoparticles (LNPs) blocks both local and distal tumor growth

Project description:Intratumoral delivery of mRNA–lipid nanoparticles (LNPs)–encoded bispecific antibodies and immunomodulatory proteins is a promising strategy for tumor eradication, offering potent local activity with limited toxicity and minimal systemic exposure. In this study, we evaluated two combinations of four immunostimulatory mRNAs and found that intratumoral administration of IL-2 and GM-CSF mRNA–LNPs together with EpCAM-CD3-Fc mRNA–LNP in OVCAR-5 and PC3 xenograft models significantly blocked the growth of not only local, treated tumors but also distant, untreated lesions. In PC3 tumors, enhanced local and systemic antitumor activity of the combination treatment was associated with activation of T-cell–related pathways, as revealed by RNA-seq analysis. Key effector genes—including perforin (PRF1), granzyme H (GZMH), CD3E, CD3D, HLA-DPA1, among others—were upregulated following treatment with the bispecific antibody plus immunomodulator mRNA–LNPs, providing mechanistic support for the observed efficacy in both local and distant tumors. Collectively, these data demonstrate that intratumoral delivery of EpCAM-CD3-Fc together with IL-2 and GM-CSF mRNA–LNPs represents a promising approach for future clinical investigation.

2026-09-04 | GSE314273 | GEO

Dexamethasone treatment of 3B4.15 T hybridoma cells

Project description:Investigation of whole genome gene expression level changes in Mus musculus 3B4.15 T hybridoma cells treated with 1microMolar Dexamethasone compared to mock treated cells. Interleukin-7 receptor alpha (IL-7Rα) is essential for T cell survival and differentiation. Glucocorticoids are potent enhancers of IL-7Rα expression with diverse roles in T cell biology. Here we identify the transcriptional repressor, Growth factor independent-1 (Gfi1), as a novel intermediary in glucocorticoid-induced IL-7Rα upregulation. We found Gfi1 to be a major inhibitory target of dexamethasone by microarray expression profiling of 3B4.15 T-hybridoma cells. Concordantly, retroviral transduction of Gfi1 significantly blunted IL-7Rα upregulation by dexamethasone. To further assess the role of Gfi1 in vivo, we generated bacterial artificial chromosome (BAC) transgenic mice, in which a modified Il7r locus expresses GFP to report Il7r gene transcription. By introducing this BAC reporter transgene into either Gfi1-deficient or Gfi1-transgenic mice, we document in vivo that IL-7Rα transcription is upregulated in the absence of Gfi1 and downregulated when Gfi1 is overexpressed. Strikingly, the in vivo regulatory role of Gfi1 was specific for CD8+, and not CD4+ T cells or immature thymocytes. These results identify Gfi1 as a specific transcriptional repressor of the Il7r gene in CD8 T lymphocytes in vivo. A six chip study using total RNA recovered from three separate flasks of mock treated 3B4.15 cells and three separate flasks of Dexamethasone treated 3B4.15 cells . Each chip measures the expression level of 44170 target genes

2012-07-12 | E-GEOD-39296 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data